Citadel Advisors
ENZN

Citadel Advisors’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Citadel Advisors’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-600
Closed -$1K – 9534
2015
Q2 		$1K Buy
+600
New +$764 ﹤0.01% 8669
2014
Q4 		– Sell
-1,800
Closed -$2K – 8948
2014
Q3 		$2K Buy
+1,800
New +$2.22K ﹤0.01% 8018
2014
Q2 		– Sell
-1,100
Closed -$1K – 8590
2014
Q1 		$1K Buy
+1,100
New +$1.14K ﹤0.01% 7789
2013
Q3 		– Sell
-1,000
Closed -$2K – 7012
2013
Q2 		$2K Buy
+1,000
New +$2.93K ﹤0.01% 6427

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.17B AUM 11.2% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citadel Advisors's ENZN Position: Q4 2015 in Review

Citadel Advisors sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q4 2015, closing a stake of 29,174 shares — an estimated $28K sold.

Citadel Advisors first reported a position in ENZN in Q2 2013 and held it in 7 quarters. The position peaked at $579K in Q1 2014. 49 funds tracked by Wall St. Rank hold ENZN as of Q4 2015.

  • Citadel Advisors reported no remaining ENZON PHARMACEUTICALS INC position as of Q4 2015 after selling out during the quarter.
  • Citadel Advisors sold 29,174 ENZON PHARMACEUTICALS INC shares in Q4 2015, an estimated $28K.
  • Citadel Advisors first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 7 quarters.
  • Citadel Advisors's ENZON PHARMACEUTICALS INC position peaked at $579K in Q1 2014.
  • 49 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q4 2015.

Based on Citadel Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.